title: Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  The benefits of the application of basiliximab induction therapy in liver transplantation are not clear. The present meta-analysis was to evaluate the pros and cons of basiliximab use in liver transplantation.
  
  
  METHODS
  We searched the associated publications in English from July 1998 to December 2015 in the following databases: MEDLINE, PubMed, Ovid, EMBASE, Web of Science and Cochrane Library.
  
  
  RESULTS
  Basiliximab significantly decreased the incidence of de novo diabetes mellitus after liver transplantation (RR=0.56; 95% CI: 0.34-0.91; P=0.02). Subgroup analysis showed that basiliximab in combination with steroids-free immunosuppressant significantly decreased the incidence of biopsy-proven acute rejection (RR=0.62; 95% CI: 0.39-0.97; P=0.04) and new-onset hypertension (RR=0.62; 95% CI: 0.42-0.93; P=0.02).
  
  
  CONCLUSIONS
  Basiliximab may be effective in reducing de novo diabetes mellitus. What is more, basiliximab in combination with steroids-free immunosuppressant shows statistical benefit to reduce biopsy-proven acute rejection and de novo hypertension.
authors.affiliation: Department of Hepatobiliary and Transplantation Surgery, First Affiliated Hospital of China Medical University, Shenyang 110001, China. jlz2000@yeah.net.
authors.forename: Guo-Qing
authors.initials: GQ
authors.lastname: Zhang
authors.forename: Cheng-Shuo
authors.initials: CS
authors.lastname: Zhang
authors.forename: Ning
authors.initials: N
authors.lastname: Sun
authors.forename: Wu
authors.initials: W
authors.lastname: Lv
authors.forename: Bao-Min
authors.initials: BM
authors.lastname: Chen
authors.forename: Jia-Lin
authors.initials: JL
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000077552:Basiliximab; D001706:Biopsy; D016009:Chi-Square Distribution; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab